Heart Failure With Reduced Ejection Fraction clinical trials

Explore recruiting heart failure with reduced ejection fraction clinical trials.

Recruiting heart failure with reduced ejection fraction studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart Failure With Reduced Ejection Fraction trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Spain, France, Poland, Germany, Greece, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (OPRA-HF)

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

(22292) Randomized, non-blinded, two-way crossover study to assess bioequivalence between finerenone 2 x 20 mg tablets and 1 x 40 mg tablet in healthy male adult participants

Germany

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Italy, Czechia, Germany, Netherlands, Hungary, Belgium +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

Portugal

Phase III and phase IV (Integrated) EU CTIS Study details

Heart Failure With Reduced Ejection Fraction trials by city

Heart Failure With Reduced Ejection Fraction in Toronto Heart Failure With Reduced Ejection Fraction in Vancouver Heart Failure With Reduced Ejection Fraction in Montreal Heart Failure With Reduced Ejection Fraction in Calgary Heart Failure With Reduced Ejection Fraction in Edmonton Heart Failure With Reduced Ejection Fraction in Ottawa Heart Failure With Reduced Ejection Fraction in Winnipeg Heart Failure With Reduced Ejection Fraction in Quebec City Heart Failure With Reduced Ejection Fraction in Hamilton Heart Failure With Reduced Ejection Fraction in Kitchener Heart Failure With Reduced Ejection Fraction in London Heart Failure With Reduced Ejection Fraction in Halifax Heart Failure With Reduced Ejection Fraction in New York Heart Failure With Reduced Ejection Fraction in Los Angeles Heart Failure With Reduced Ejection Fraction in Chicago Heart Failure With Reduced Ejection Fraction in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease